Abu Dhabi, October 10-11, 2024 – Continuing his groundbreaking tour of Abu Dhabi, renowned bio-regenerative medicine expert Prof. Mike Chan spent two days visiting the emirate’s top healthcare institutions, furthering discussions on collaboration and innovation in the medical field.
He was accompanied by the European Wellness (EW) team, including Prof. Dr. Dmitry Klokol, Head of the Medical Advisory Board, and Dr. Bawani Nesamany, Education Medical Director. Also present was His Excellency Khalid Mubarak Albuainain Almazrouie, the chief advisor in the UAE, who played a crucial role in facilitating the visit and ensuring its success.
Day 4: October 10, 2024
The day began with a tour of BioGenix Labs, a subsidiary of G42 Healthcare, located in Masdar City. The lab, known for its high-throughput testing during the COVID-19 pandemic and its pioneering work in genomic research and AI-driven diagnostics, welcomed Prof. Chan and his team. During his visit, Prof. Chan gave a presentation on targeted organ and precursor stem cell therapies, emphasizing the potential for advanced diagnostics to complement regenerative treatments.
“BioGenix Labs represents the future of diagnostics, and their innovations in genomic research are critical to advancing personalized healthcare,” Prof. Chan remarked. “We are witnessing a convergence of precision diagnostics and regenerative medicine, which will ultimately lead to better, more effective treatments for patients.”
Following the tour of BioGenix Labs, Prof. Chan was introduced to the M42 initiative, a cutting-edge healthcare program that combines AI, genomics, and data analytics to deliver personalized, patient-centric care. The M42 initiative mirrors much of Prof. Chan’s work in bio-regenerative medicine, focusing on using technology to enhance health outcomes and create more targeted treatment solutions.
Later in the afternoon, Prof. Chan visited the Dubai Department of Health, where he engaged in a meeting with Dr. Asma Al-Mannaei Executive Director Research and Innovation Center, and other key officials. The discussions centered on potential collaborations to advance stem cell research and personalized treatments. Prof. Chan also explored the regulatory frameworks and public health initiatives in the UAE, which align with his work in bio-regenerative medicine.
“This is an exciting time for healthcare. Abu Dhabi is at the forefront of regulatory advancements and public health initiatives that align perfectly with the work we are doing in bio-regenerative medicine,” said Prof. Chan. “There is immense potential here for joint efforts that could revolutionize how we approach healthcare, particularly in personalized medicine.”
The day concluded with a private dinner session hosted by His Excellency Dr. Khalid Mubarak at his residence, providing an opportunity to deepen discussions on future collaboration between European Wellness and Abu Dhabi’s healthcare leaders.
Day 5: October 11, 2024
On the final day of his tour, Prof. Chan visited the Abu Dhabi Department of Health where he gave a presentation on stem cell and peptide therapies to a gathering of senior specialists, surgeons, doctors, and clinicians. His 30-minute lecture focused on the breakthroughs and future potential of bio-regenerative medicine, particularly in stem cell therapies, followed by a 30-minute Q&A session that provided further insights into the impact of these treatments on modern healthcare.
“The response from the medical community here in Abu Dhabi has been overwhelmingly positive,” said Prof. Chan. “It’s clear that there is a shared commitment to advancing healthcare through innovative treatments, and I look forward to seeing the collaborations that come from these discussions.”
This final presentation was seen as a significant moment of the tour, offering a platform for meaningful exchanges between Prof. Chan and Abu Dhabi’s medical community on topics that will shape the future of regenerative medicine.
With the conclusion of the visit, Prof. Chan’s tour underscored Abu Dhabi’s growing role as a leader in global healthcare innovation. His visits to BioGenix Labs, the M42 initiative, and the Department of Health highlighted the immense potential for international collaborations aimed at revolutionizing healthcare delivery and elevating standards worldwide.
“This is only the beginning,” Prof. Chan said. “The work we are doing today will lay the foundation for future breakthroughs in healthcare, and Abu Dhabi will undoubtedly play a central role in that future.”
Comments are closed.